Honored with the Kramer-Pollnow Prize by @eunethydis! A heartfelt thank you to the organisation and to the brilliant minds in the field who inspire me every day. Grateful for this incredible recognition. #KramerPollnowPrize #ADHD

Our study using data from the UK CPRD Aurum published in @CIDJournal shows that metformin use within 90 days of COVID-19 diagnosis reduces post-COVID risk in individuals with overweight/obesity. 📮Read more: https://t.co/eXxp6ohpv7 @ChengshengJ @LiWeiUCL @KennethKCMan

"Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan", has been published by our international team! Read

Our multinational network cohort study shows that extensive multi-organ involvement of post-COVID-19 condition over the short-term period and the subside in risk for most complications over the medium- and long-term.

🌍 Exciting PhD studentship at UCL School of Pharmacy! Join the GENESIS project, a global collaboration using real-world data to advance mental health & maternal-child health research. #PhD #Epidemiology #RegulatoryScience 🔗

The fifth and final member of our OPERA 2025 shortlist, @wallis_lau, was lauded by judges for her research’s influence on prescribing recommendations, ensuring safer anticoagulant use. Read more here: https://t.co/Ip5oIEetWC The overall winner will be announced on 30 June 2025 🏆

Our latest multinational study on trends in survival after #Dementia diagnosis has just been published with @SpringerNature in @CommsMedicine Read here: https://t.co/B1LWgZI8Cf @Ian_HKU @ChuiCeline @KennethKCMan @Knappem @GloW_hk

The findings of this new study do not support a direct effect of gabapentinoid treatment on self-harm but underscore the necessity for close patient monitoring of self-harm throughout the gabapentinoid treatment journey @KennethKCMan https://t.co/oJgIipCBKS

Treatment with gabapentinoids isn't directly associated with an increased risk of self-harm, finds this study. However, rates of self-harm were higher before and shortly after treatment, highlighting the need for close monitoring of patients @KennethKCMan https://t.co/oJgIipCBKS

New in @bmj_latest: Gabapentinoid treatment not directly linked to increased self-harm risk. Risk is highest before and after treatment—not during. Close monitoring needed across the full treatment journey. Read more:

🧠 #TIMESPAN is transforming #ADHD research. By uniting global data, we explore ADHD's impact on cardiometabolic conditions, capture treatment variations, and drive better outcomes worldwide. #ADHDResearch #GlobalHealth ➡ Full blog post: https://t.co/IbEGbRrVYT

🚨 'Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation' published in @PLOSMedicine

PhD Opportunity @UCL 🌍 Join our global collaboration with SKKU & partners, tackling key health challenges in mental health & maternal-child health using real-world data! 💡 Open to passionate candidates in epidemiology, stats, pharmacy & more! @FindAPhD:

🚨 'Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000–2019: 20-year investigation of who receives treatment, with which agents and at what doses' now published in @TheBJPsych

Metformin was associated with a lower rate of asthma attacks, with further reductions with the use of GLP-1RA. https://t.co/JMxHHQmh7y

A very nice study by @BoheeLEE4 and @chloebloom using multiple study designs (self-controlled case series & cohort analysis) showed consistent results: metformin lowered asthma attack risk by ~30%, with GLP-1RA adding 40%. A robust approach to observational data!

Great study lead by @fredho42 looked into factors contributing to the association between deprivation and infant death. Targeting moderating factors may mitigate some the effects but will not stem the rise in infant mortality. #heathinequalities https://t.co/WoQq5GzJRW

I was an ad-hoc reviewer in June 2023 and then was invited to be an ERC core member in Feb 2024. Happy to take one step further as ERC chair for CPRD.

https://t.co/kAjSGU8knr @Ian_HKU @HaoLuo429 @J_F_Hayes @wallis_lau @ChuiCeline @slseager78

Our new @OHDSI study in Lancet Psychiatry found that the prescribing rates of anxiolytics during the COVID-19 pandemic were persistently elevated, underscore the importance of enhanced mental health support and regular review of psychotropic drug use in the post-pandemic era.

Our latest work summarises evidence on sex-based outcomes of anticoagulants in AF. We had to dive into full texts & appendices of >500 papers to find sex-based results. Couldn’t have done this without the team @J_Chobanov @PajareeMaii Edil @ZixuanWang_ZW! https://t.co/9X43EST2Kp